Nanotechnology is relatively new to the scientific world but already has the potential to significantly alter healthcare. By working with near atom-sized particles, scientists and doctors can deliver drugs more effectively and target specific organs, diagnose diseases more rapidly and with greater sensitivity, and deliver vaccines through aerosols and transdermal patches.
The physical and chemical properties of materials in the nanoscale are radically different. They have different strengths, conductivity, and reactivity, and it is these properties that are being utilized in biomedical research. Increased activity is causing expansion in the market: BCC Research expects the global nanoparticles in biotechnology, drug development, and drug delivery systems market to reach $156.8 billion by 2028 up from $102.7 billion in 2023. The market will expand at a compound annual growth rate (CAGR) of 8.8% for the forecast period of 2023 to 2028.
BCC Research has identified these ten companies as being the top presences in the nanotechnology landscape:
Bristol-Myers Squibb is a global biopharmaceutical company and a key player in the nanoparticle space. The company discovers, develops, manufactures, and distributes pharmaceutical and other healthcare products, and has a strong portfolio across oncology, cardiovascular, immunoscience, and virology products. The company has a leading market position in the pharmaceutical and healthcare market. 2019 was a transformative year for Bristol-Myers Squibb, as it acquired Celgene in one of the largest mergers ever in its sector.
Camurus AB is a research-oriented pharmaceutical and biotechnology company located in Lund, Sweden. The company develops drugs to address serious unmet medical needs. These drugs cover a range of therapeutic areas, including cancer, endocrinology, pain, metabolic disease, and drug addiction. Camurus has developed two novel platforms for the delivery of nanoparticle and nanocrystal drugs. The firm’s R&D pipeline is strong and includes drugs for the treatment of opioid dependence, pain, rare diseases, endocrine diseases, and cancer. Camurus’ strategy is to continue developing drugs to meet the needs of its target disease category areas.
Ceramisphere Health is a privately owned Australian company that focuses on commercializing patented technology for the encapsulation, transport, delivery, and controlled release of molecules based on sub-micron ceramic (e.g., silica) microspheres. The company is a leader in the field of sol-gel chemistry. It is currently working on the application of this technology to a range of commercial opportunities. In its state-of-the-art R&D facilities in Sydney, it undertakes product development and also scale-up, production, and testing of its novel encapsulated products.